EMEA-002903-PIP03-21
Key facts
| Active substance |
Anti-C1s Humanized IgG4 Monoclonal Antibody
|
| Therapeutic area |
|
| Decision number |
P/0434/2021
|
| PIP number |
EMEA-002903-PIP03-21
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of chronic inflammatory demyelinating polyradiculo-neuropathy
|
| Route(s) of administration |
|
| Contact for public enquiries |
Genzyme Europe B.V.
E-mail: eumedinfo.gz@sanofi.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|